MUC1-CT mediates corticosteroid responses in COPD

Lucia Diaz (A coruña, Spain), Lucia Diaz, Javier Milara, Esteban Morcillo, Adela Serrano, Ricardo Guijarro, Celia Sanz, Julio Cortijo

Source: International Congress 2016 – Preclinical pharmacology: drug targets and mechanisms of action
Session: Preclinical pharmacology: drug targets and mechanisms of action
Session type: Thematic Poster
Number: 4095
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Lucia Diaz (A coruña, Spain), Lucia Diaz, Javier Milara, Esteban Morcillo, Adela Serrano, Ricardo Guijarro, Celia Sanz, Julio Cortijo. MUC1-CT mediates corticosteroid responses in COPD. Eur Respir J 2016; 48: Suppl. 60, 4095

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Irisin is associated with severe exacerbations of COPD independently of lung function, comorbidities and exercise capacity
Source: International Congress 2015 – Notable abstracts in COPD: variety
Year: 2015

Symptom profile of exacerbations in earlier and later COPD
Source: Annual Congress 2013 –Asthma and COPD: diseases with different phenotypes
Year: 2013


Do inhaled corticosteroids reduce the frequent exacerbator phenotype in COPD - A little help by a multicenter survey
Source: International Congress 2016 – Biomarkers and phenotypes of COPD
Year: 2016

Clinical and inflammatory characteristics of 'unreported' COPD exacerbations
Source: Annual Congress 2013 –COPD mechanisms
Year: 2013


Increased circulating alveolar epithelial microparticles in COPD patients
Source: International Congress 2015 – Modulating the immune system in COPD and asthma
Year: 2015

Comparative study of hospitalized patients with acute exacerbation of COPD with and without carbon dioxide retention
Source: Annual Congress 2013 –COPD treatment and others
Year: 2013


IL-17A is specifically elevated in NTHi-associated AECOPD and end-stage COPD
Source: International Congress 2015 – Modulating the immune system in COPD and asthma
Year: 2015

Altered expression of glycosaminoglycans in the BAL of COPD patients with acute exacerbation
Source: Annual Congress 2013 –Translational studies in chronic lung diseases: from bedside to bench
Year: 2013

The role of IFN-γ in severe COPD patients with anamnestic viral-induced exacerbations before and after roflumilast treatment
Source: International Congress 2016 – Translational studies in lung disease
Year: 2016

RT protocol reduces AECOPD readmissions
Source: International Congress 2016 – In-patient and out-patient COPD management
Year: 2016


COPD exacerbation: Influence of severity and type of systemic inflammation on the hospitalizations rate
Source: International Congress 2015 – COPD: chronic disease and comorbidities
Year: 2015

The serum level of surfactantproteind in patients with chronic obstructive pulmonary disease, depending on the nutrtional status
Source: International Congress 2015 – Notable abstracts in exacerbations, mechanisms and biomarkers in COPD
Year: 2015


QVA149 reduces COPD exacerbation rate in various subgroups of patients: The SPARK study
Source: Annual Congress 2013 –New bronchodilators for COPD management
Year: 2013



CAT in COPD phenotypes (POPE study)
Source: International Congress 2016 – Phenotyping and monitoring airway diseases
Year: 2016


Frequency of COPD exacerbations and severity of COPD
Source: Annual Congress 2013 –Predictors and triggers of asthma and COPD exacerbations
Year: 2013


The bronchitic phenotype is associated with frequent exacerbations in COPD irrespective of chronic bacterial airway infection
Source: Annual Congress 2013 –Guidelines and exacerbations
Year: 2013

A pilot study of CPAP therapy for excessive dynamic airway collapse during acute exacerbation of COPD
Source: International Congress 2014 – COPD - from biomarkers to novel therapeutic opportunities
Year: 2014



FEV1 decline in patients with chronic obstructive pulmonary disease: Which treatment option is better for slowing of decline?
Source: International Congress 2015 – COPD: exacerbations, gas exchange and associated dysfunction
Year: 2015


Are there any differences between Tunisian and European COPD phenotypes?
Source: International Congress 2016 – Best abstracts in COPD management
Year: 2016


COPD on anti-GERD therapy remains at higher risk for severe exacerbation
Source: International Congress 2014 – COPD exacerbations
Year: 2014